JP2709761B2 - 甲状腺刺激ホルモン抑制および甲状腺腫治療用薬剤 - Google Patents
甲状腺刺激ホルモン抑制および甲状腺腫治療用薬剤Info
- Publication number
- JP2709761B2 JP2709761B2 JP3235466A JP23546691A JP2709761B2 JP 2709761 B2 JP2709761 B2 JP 2709761B2 JP 3235466 A JP3235466 A JP 3235466A JP 23546691 A JP23546691 A JP 23546691A JP 2709761 B2 JP2709761 B2 JP 2709761B2
- Authority
- JP
- Japan
- Prior art keywords
- thyronine
- diiodo
- goiter
- stimulating hormone
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 206010018498 Goitre Diseases 0.000 title claims abstract description 10
- 201000003872 goiter Diseases 0.000 title claims abstract description 10
- 230000001629 suppression Effects 0.000 title claims abstract 3
- 239000003814 drug Substances 0.000 title claims description 7
- 102000011923 Thyrotropin Human genes 0.000 title description 15
- 108010061174 Thyrotropin Proteins 0.000 title description 15
- 229940079593 drug Drugs 0.000 title description 5
- 210000001685 thyroid gland Anatomy 0.000 claims description 7
- KKCIOUWDFWQUBT-AWEZNQCLSA-N L-thyronine Chemical compound C1=CC(C[C@H](N)C(O)=O)=CC=C1OC1=CC=C(O)C=C1 KKCIOUWDFWQUBT-AWEZNQCLSA-N 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- ZHSOTLOTTDYIIK-ZDUSSCGKSA-N (2S)-2-amino-3-[4-(4-hydroxyphenoxy)-3,5-diiodophenyl]propanoic acid Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C=C1 ZHSOTLOTTDYIIK-ZDUSSCGKSA-N 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 14
- 239000002207 metabolite Substances 0.000 abstract description 2
- 230000007774 longterm Effects 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 10
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 229940034208 thyroxine Drugs 0.000 description 6
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 6
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010077065 Glycerol-1-phosphate dehydrogenase Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000001729 effect on metabolism Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 206010043688 thyroid adenoma Diseases 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 229940035722 triiodothyronine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Radio Relay Systems (AREA)
- Bakery Products And Manufacturing Methods Therefor (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Microwave Tubes (AREA)
- Superconductors And Manufacturing Methods Therefor (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4026600A DE4026600A1 (de) | 1990-08-23 | 1990-08-23 | Mittel zur tsh-suppression und behandlung von struma |
| DE4026600.1 | 1990-08-23 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH04244022A JPH04244022A (ja) | 1992-09-01 |
| JP2709761B2 true JP2709761B2 (ja) | 1998-02-04 |
Family
ID=6412712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP3235466A Expired - Lifetime JP2709761B2 (ja) | 1990-08-23 | 1991-08-22 | 甲状腺刺激ホルモン抑制および甲状腺腫治療用薬剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US5200428A (enExample) |
| EP (1) | EP0472033B1 (enExample) |
| JP (1) | JP2709761B2 (enExample) |
| AT (1) | ATE131729T1 (enExample) |
| DE (2) | DE4026600A1 (enExample) |
| DK (1) | DK0472033T3 (enExample) |
| ES (1) | ES2083490T3 (enExample) |
| GR (1) | GR3018705T3 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19541128C2 (de) * | 1995-10-27 | 1997-11-27 | Henning Berlin Gmbh & Co | Stabilisierte schilddrüsenhormonhaltige Arzneimittel |
| US6740680B1 (en) * | 1999-04-26 | 2004-05-25 | Becton Pharma, Inc. | Pharmaceutical compositions to tetrac and methods of use thereof |
| ITMI20011401A1 (it) | 2001-07-02 | 2003-01-02 | Altergon Sa | Formulazioni farmaceutiche per ormoni tiroidei |
| ITMI20022777A1 (it) * | 2002-12-27 | 2004-06-28 | Altergon Sa | Formulazioni farmaceutiche per ormoni tiroidei e procedimenti per il loro ottenimento. |
| ITRM20030363A1 (it) * | 2003-07-24 | 2005-01-25 | Fernando Goglia | Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse. |
| DE102010018514A1 (de) | 2010-04-27 | 2011-10-27 | Nordischer Maschinenbau Rud. Baader Gmbh + Co Kg | Vorrichtung und Verfahren zum Trennen einer Oberflächenschicht von tierischen Nahrungsmittelprodukten |
| CN104784427A (zh) * | 2015-05-19 | 2015-07-22 | 李汶峰 | 一种治疗甲状腺囊肿的中药 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3102136A (en) * | 1959-06-24 | 1963-08-27 | Warner Lambert Pharmaceutical | Process of preparing diiodinated analogs of thyronine |
| US4673691A (en) * | 1984-11-05 | 1987-06-16 | Nicholas Bachynsky | Human weight loss inducing method |
| CN1011118B (zh) * | 1986-06-13 | 1991-01-09 | 天津医学院附属医院 | 治疗白内障的眼药水的制药方法 |
-
1990
- 1990-08-23 DE DE4026600A patent/DE4026600A1/de active Granted
-
1991
- 1991-08-02 EP EP91113017A patent/EP0472033B1/de not_active Expired - Lifetime
- 1991-08-02 DK DK91113017.7T patent/DK0472033T3/da active
- 1991-08-02 ES ES91113017T patent/ES2083490T3/es not_active Expired - Lifetime
- 1991-08-02 DE DE59107111T patent/DE59107111D1/de not_active Expired - Fee Related
- 1991-08-02 AT AT91113017T patent/ATE131729T1/de not_active IP Right Cessation
- 1991-08-22 JP JP3235466A patent/JP2709761B2/ja not_active Expired - Lifetime
- 1991-08-23 US US07/748,882 patent/US5200428A/en not_active Expired - Fee Related
-
1996
- 1996-01-17 GR GR960400106T patent/GR3018705T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GR3018705T3 (en) | 1996-04-30 |
| EP0472033B1 (de) | 1995-12-20 |
| DK0472033T3 (da) | 1996-01-29 |
| DE4026600C2 (enExample) | 1992-06-04 |
| EP0472033A2 (de) | 1992-02-26 |
| US5200428A (en) | 1993-04-06 |
| DE59107111D1 (de) | 1996-02-01 |
| DE4026600A1 (de) | 1992-02-27 |
| JPH04244022A (ja) | 1992-09-01 |
| EP0472033A3 (en) | 1992-07-15 |
| ATE131729T1 (de) | 1996-01-15 |
| ES2083490T3 (es) | 1996-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5719122A (en) | Pharmaceutical compositions containing a calcitonin | |
| Tomas et al. | Effect of glucocorticoid administration on the rate of muscle protein breakdown in vivo in rats, as measured by urinary excretion of N τ-methylhistidine | |
| US5834032A (en) | Compositions and methods for treating diabetes | |
| JPH02101022A (ja) | 糖尿病治療用医薬組成物 | |
| Bartholini et al. | The stereoisomers of 3, 4-dihydroxyphenylserine as precursors of norepinephrine. | |
| TW201100093A (en) | Preparation comprising insulin, nicotinamide and an amino acid | |
| AU2159399A (en) | Utilization of alkyl hydrogen fumerates for treating psoriasis, psoriatic arthritis, neurodermatitis and regional enteritis | |
| KR960000219A (ko) | 당뇨병 합병증 치료용 조성물 | |
| EP0252290A2 (en) | Pharmaceutical compositions containing levodopa methyl ester, preparation and therapeutic applications thereof | |
| EP0404807A1 (en) | DEPRENYLE FOR SYSTEMIC TRANSDERMAL ADMINISTRATION. | |
| EP0742714A1 (en) | Liquid pharmaceutical compositions comprising thyroid hormones | |
| GB2095555A (en) | Prevention of body fat deposition in mammals | |
| WO2013033194A1 (en) | Levothyroxine formulations | |
| JPS6321648B2 (enExample) | ||
| CA2118030C (en) | Drug for increasing the level of testosterone in the body | |
| JPH04244022A (ja) | 甲状腺刺激ホルモン抑制および甲状腺腫治療用薬剤 | |
| KR970061249A (ko) | 골다공증을 치료 또는 방지하기 위한 조성물 | |
| US2987442A (en) | Method of treating hypertension with [2-(2, 6-dimethylphenoxy)-propyl]-trimethyl ammonium salts | |
| JPS60120995A (ja) | 新規アミノ酸誘導体の製法 | |
| CA3191276A1 (en) | Ionic liquid formulations for treating diabetes | |
| WO2024230460A1 (zh) | 五环三萜结构修饰化合物在制备白癜风药物中的应用及新制剂 | |
| Lerman et al. | The physiologic activity of tetrabrom-thyronine and tetrachlorthyronine | |
| EP0607229A1 (en) | Pharmaceutical compositions comprising a calcitonin, a glycyrrhizinate as absorption enhancer and benzyl | |
| US4122188A (en) | Treatment of hyperlipoproteinemia with a dichloroacetate salt | |
| US2776923A (en) | Composition comprising glutamylcholine salts |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 19970902 |